CN104946779B - 一种检测HLA-B*57:01等位基因的TaqMan探针实时荧光PCR方法 - Google Patents
一种检测HLA-B*57:01等位基因的TaqMan探针实时荧光PCR方法 Download PDFInfo
- Publication number
- CN104946779B CN104946779B CN201510411972.4A CN201510411972A CN104946779B CN 104946779 B CN104946779 B CN 104946779B CN 201510411972 A CN201510411972 A CN 201510411972A CN 104946779 B CN104946779 B CN 104946779B
- Authority
- CN
- China
- Prior art keywords
- probe
- hla
- primer
- allele
- gene
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000000523 sample Substances 0.000 title claims abstract description 102
- 238000001514 detection method Methods 0.000 title claims abstract description 34
- 238000000034 method Methods 0.000 title claims abstract description 33
- 108700028369 Alleles Proteins 0.000 title claims description 43
- 108010033369 HLA-B57 antigen Proteins 0.000 title claims description 30
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 39
- 230000003321 amplification Effects 0.000 claims abstract description 22
- 238000003199 nucleic acid amplification method Methods 0.000 claims abstract description 18
- 238000006243 chemical reaction Methods 0.000 claims abstract description 13
- 108091005904 Hemoglobin subunit beta Proteins 0.000 claims abstract description 12
- 102100021519 Hemoglobin subunit beta Human genes 0.000 claims abstract description 8
- 102210024052 HLA-B*57:01 Human genes 0.000 claims description 32
- 238000013461 design Methods 0.000 claims description 11
- 238000003753 real-time PCR Methods 0.000 claims description 8
- UDGUGZTYGWUUSG-UHFFFAOYSA-N 4-[4-[[2,5-dimethoxy-4-[(4-nitrophenyl)diazenyl]phenyl]diazenyl]-n-methylanilino]butanoic acid Chemical compound COC=1C=C(N=NC=2C=CC(=CC=2)N(C)CCCC(O)=O)C(OC)=CC=1N=NC1=CC=C([N+]([O-])=O)C=C1 UDGUGZTYGWUUSG-UHFFFAOYSA-N 0.000 claims description 5
- BZTDTCNHAFUJOG-UHFFFAOYSA-N 6-carboxyfluorescein Chemical compound C12=CC=C(O)C=C2OC2=CC(O)=CC=C2C11OC(=O)C2=CC=C(C(=O)O)C=C21 BZTDTCNHAFUJOG-UHFFFAOYSA-N 0.000 claims description 4
- 230000009977 dual effect Effects 0.000 claims description 4
- 238000000605 extraction Methods 0.000 claims description 3
- 238000003908 quality control method Methods 0.000 claims description 3
- 239000013589 supplement Substances 0.000 claims description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 3
- 230000007850 degeneration Effects 0.000 claims description 2
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 238000001917 fluorescence detection Methods 0.000 claims 1
- 230000035945 sensitivity Effects 0.000 abstract description 5
- 238000013211 curve analysis Methods 0.000 abstract 1
- 108020004414 DNA Proteins 0.000 description 28
- MCGSCOLBFJQGHM-SCZZXKLOSA-N abacavir Chemical compound C=12N=CN([C@H]3C=C[C@@H](CO)C3)C2=NC(N)=NC=1NC1CC1 MCGSCOLBFJQGHM-SCZZXKLOSA-N 0.000 description 11
- 229960004748 abacavir Drugs 0.000 description 11
- 239000003814 drug Substances 0.000 description 10
- 102100028976 HLA class I histocompatibility antigen, B alpha chain Human genes 0.000 description 9
- 108010058607 HLA-B Antigens Proteins 0.000 description 9
- 229940079593 drug Drugs 0.000 description 9
- 238000002474 experimental method Methods 0.000 description 8
- 238000012163 sequencing technique Methods 0.000 description 7
- 238000012360 testing method Methods 0.000 description 6
- 210000004369 blood Anatomy 0.000 description 5
- 239000008280 blood Substances 0.000 description 5
- 238000005516 engineering process Methods 0.000 description 4
- 230000002068 genetic effect Effects 0.000 description 4
- 230000013011 mating Effects 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 238000010790 dilution Methods 0.000 description 3
- 239000012895 dilution Substances 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 206010020751 Hypersensitivity Diseases 0.000 description 2
- 108700018351 Major Histocompatibility Complex Proteins 0.000 description 2
- 108091028043 Nucleic acid sequence Proteins 0.000 description 2
- 238000000246 agarose gel electrophoresis Methods 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 239000000427 antigen Substances 0.000 description 2
- 108091007433 antigens Proteins 0.000 description 2
- 102000036639 antigens Human genes 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 229960001484 edetic acid Drugs 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 239000013062 quality control Sample Substances 0.000 description 2
- 230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 208000030507 AIDS Diseases 0.000 description 1
- 208000006820 Arthralgia Diseases 0.000 description 1
- 230000004544 DNA amplification Effects 0.000 description 1
- 238000007400 DNA extraction Methods 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 208000031886 HIV Infections Diseases 0.000 description 1
- 102000006354 HLA-DR Antigens Human genes 0.000 description 1
- 108010058597 HLA-DR Antigens Proteins 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 241000725303 Human immunodeficiency virus Species 0.000 description 1
- 208000001953 Hypotension Diseases 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 208000030961 allergic reaction Diseases 0.000 description 1
- 230000002052 anaphylactic effect Effects 0.000 description 1
- 230000002155 anti-virotic effect Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 238000003759 clinical diagnosis Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- 239000000890 drug combination Substances 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 230000004907 flux Effects 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 238000013412 genome amplification Methods 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 230000009610 hypersensitivity Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 208000012866 low blood pressure Diseases 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000002974 pharmacogenomic effect Effects 0.000 description 1
- 238000003752 polymerase chain reaction Methods 0.000 description 1
- 102000054765 polymorphisms of proteins Human genes 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 239000003419 rna directed dna polymerase inhibitor Substances 0.000 description 1
- 239000012898 sample dilution Substances 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 238000000870 ultraviolet spectroscopy Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
- C12Q1/701—Specific hybridization probes
- C12Q1/702—Specific hybridization probes for retroviruses
- C12Q1/703—Viruses associated with AIDS
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6844—Nucleic acid amplification reactions
- C12Q1/6858—Allele-specific amplification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Virology (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- AIDS & HIV (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
Description
Claims (7)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201510411972.4A CN104946779B (zh) | 2015-07-14 | 2015-07-14 | 一种检测HLA-B*57:01等位基因的TaqMan探针实时荧光PCR方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201510411972.4A CN104946779B (zh) | 2015-07-14 | 2015-07-14 | 一种检测HLA-B*57:01等位基因的TaqMan探针实时荧光PCR方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN104946779A CN104946779A (zh) | 2015-09-30 |
CN104946779B true CN104946779B (zh) | 2018-06-12 |
Family
ID=54161841
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201510411972.4A Active CN104946779B (zh) | 2015-07-14 | 2015-07-14 | 一种检测HLA-B*57:01等位基因的TaqMan探针实时荧光PCR方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN104946779B (zh) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106636370A (zh) * | 2016-11-30 | 2017-05-10 | 武汉海吉力生物科技有限公司 | 用于检测人类hla‑b*5701等位基因的核酸、试剂盒及方法 |
CN110951864A (zh) * | 2019-12-26 | 2020-04-03 | 陕西佰美基因股份有限公司 | 一种检测ANNK1基因rs1800497位点的实时荧光PCR方法及其引物探针组合 |
Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102660635A (zh) * | 2012-01-14 | 2012-09-12 | 长沙三济生物科技有限公司 | 一种定性检测hla-b*1502基因亚型的荧光pcr试剂盒 |
CN102834525A (zh) * | 2009-11-16 | 2012-12-19 | 美国基因组学有限公司 | 使用未经加工的血液的pcr和hla分型的方法 |
CN103184291A (zh) * | 2013-04-07 | 2013-07-03 | 上海血液生物医药有限责任公司 | 一种检测人hla-b*57:01等位基因的试剂盒 |
CN103215356A (zh) * | 2013-04-07 | 2013-07-24 | 上海血液生物医药有限责任公司 | 一种检测人hla-b*57:01和hcp5等位基因的试剂盒 |
CN104232781A (zh) * | 2014-09-26 | 2014-12-24 | 陕西佰美基因股份有限公司 | 一种检测HLA-B*5801等位基因的TaqMan探针实时荧光PCR方法 |
CN104293932A (zh) * | 2014-09-26 | 2015-01-21 | 陕西佰美基因股份有限公司 | 一种基于实时荧光pcr检测hla-b*5801等位基因的方法 |
KR20150017149A (ko) * | 2013-08-06 | 2015-02-16 | 인제대학교 산학협력단 | 약물 부작용과 관련된 HLA 대립유전자의 tSNP를 이용한 고속 검출 방법 |
WO2015022669A2 (en) * | 2013-08-15 | 2015-02-19 | Centre Hospitalier Universitarie Vaudois | Methods for typing hla alleles |
-
2015
- 2015-07-14 CN CN201510411972.4A patent/CN104946779B/zh active Active
Patent Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102834525A (zh) * | 2009-11-16 | 2012-12-19 | 美国基因组学有限公司 | 使用未经加工的血液的pcr和hla分型的方法 |
CN102660635A (zh) * | 2012-01-14 | 2012-09-12 | 长沙三济生物科技有限公司 | 一种定性检测hla-b*1502基因亚型的荧光pcr试剂盒 |
CN103184291A (zh) * | 2013-04-07 | 2013-07-03 | 上海血液生物医药有限责任公司 | 一种检测人hla-b*57:01等位基因的试剂盒 |
CN103215356A (zh) * | 2013-04-07 | 2013-07-24 | 上海血液生物医药有限责任公司 | 一种检测人hla-b*57:01和hcp5等位基因的试剂盒 |
KR20150017149A (ko) * | 2013-08-06 | 2015-02-16 | 인제대학교 산학협력단 | 약물 부작용과 관련된 HLA 대립유전자의 tSNP를 이용한 고속 검출 방법 |
WO2015022669A2 (en) * | 2013-08-15 | 2015-02-19 | Centre Hospitalier Universitarie Vaudois | Methods for typing hla alleles |
CN104232781A (zh) * | 2014-09-26 | 2014-12-24 | 陕西佰美基因股份有限公司 | 一种检测HLA-B*5801等位基因的TaqMan探针实时荧光PCR方法 |
CN104293932A (zh) * | 2014-09-26 | 2015-01-21 | 陕西佰美基因股份有限公司 | 一种基于实时荧光pcr检测hla-b*5801等位基因的方法 |
Also Published As
Publication number | Publication date |
---|---|
CN104946779A (zh) | 2015-09-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN106119413B (zh) | 一种艾滋病病毒多重荧光pcr检测试剂盒及检测方法 | |
CN104232781B (zh) | 一种检测HLA‑B*5801等位基因的TaqMan探针实时荧光PCR方法 | |
CN102534031B (zh) | 一种高特异性聋病易感基因检测试剂盒及其应用 | |
CN104830852B (zh) | 一种检测hla‑b*15:02等位基因的多重实时荧光pcr方法 | |
CN109097463B (zh) | 一种用于检测hla-a*24:02等位基因的特异性引物探针组合、试剂盒及检测方法 | |
CN110964799B (zh) | 用于检测人类血小板表面抗原hpa与hla-ab基因分型的试剂盒 | |
CN109055532A (zh) | 胚胎植入前遗传性耳聋基因检测用引物组合物、试剂盒及应用 | |
CN106399479A (zh) | 一种用于ⅱ型糖尿病易感基因检测的snp分型试剂盒 | |
CN106939334B (zh) | 一种孕妇血浆中胎儿dna含量的检测方法 | |
CN104946779B (zh) | 一种检测HLA-B*57:01等位基因的TaqMan探针实时荧光PCR方法 | |
WO2008077329A1 (fr) | Sonde destinée à détecter la mutation a1555g de surdité génétique mitochondriale héritée de la mère et son utilisation | |
CN104293932A (zh) | 一种基于实时荧光pcr检测hla-b*5801等位基因的方法 | |
CN104962641B (zh) | 一种检测hla‑b*13:01等位基因的多重实时荧光pcr方法 | |
CN103451302A (zh) | 聋病易感基因线粒体12SrDNA 1555A>G、1494C>T突变比例检测试剂盒 | |
CN111073964B (zh) | 用于检测人类白细胞抗原hla-abcdrdq基因分型的试剂盒 | |
JP6164683B2 (ja) | Y染色体及びy染色体上精子形成領域の欠失部位の分析方法 | |
CN111235261B (zh) | 用于检测人类血小板特异性抗原hpa 1~29基因分型的试剂盒 | |
CN108531647A (zh) | 一种寨卡病毒一步法荧光rt-PCR检测方法及试剂盒 | |
CN104046699A (zh) | F9基因拷贝数变异检测试剂盒 | |
CN102534030B (zh) | 4个聋病易感基因联合检测试剂盒及其应用 | |
CN108660252A (zh) | 一种基于焦磷酸测序的人类免疫缺陷病毒耐药性分析方法 | |
CN104232774A (zh) | 用于检测乳腺癌易感基因snp的引物、荧光探针及应用 | |
KR102076343B1 (ko) | 실시간 lamp법을 이용한 아데노바이러스 55형 검출용 조성물 및 이의 용도 | |
CN102660636A (zh) | 一种聋病易感基因12S rRNA 1555A>G荧光检测试剂盒及其应用 | |
CN106755530A (zh) | 一种检测hla‑a*31:01等位基因的mgb探针实时荧光pcr方法及其引物探针组合 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
PE01 | Entry into force of the registration of the contract for pledge of patent right | ||
PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: TaqMan probe real-time fluorescent PCR method for detecting HLA-B*57:01 allele Effective date of registration: 20190729 Granted publication date: 20180612 Pledgee: Xi'an innovation financing Company limited by guarantee Pledgor: SHAANXI LIFEGEN Co.,Ltd. Registration number: 2019990000797 |
|
PC01 | Cancellation of the registration of the contract for pledge of patent right |
Date of cancellation: 20210810 Granted publication date: 20180612 Pledgee: Xi'an innovation financing Company limited by guarantee Pledgor: SHAANXI LIFEGEN Co.,Ltd. Registration number: 2019990000797 |
|
PC01 | Cancellation of the registration of the contract for pledge of patent right | ||
PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: TaqMan probe real-time fluorescence PCR method for detecting HLA-B * 57:01 allele Effective date of registration: 20211019 Granted publication date: 20180612 Pledgee: Xi'an innovation financing Company limited by guarantee Pledgor: SHAANXI LIFEGEN Co.,Ltd. Registration number: Y2021990000958 |
|
PE01 | Entry into force of the registration of the contract for pledge of patent right | ||
PC01 | Cancellation of the registration of the contract for pledge of patent right |
Date of cancellation: 20230612 Granted publication date: 20180612 Pledgee: Xi'an innovation financing Company limited by guarantee Pledgor: SHAANXI LIFEGEN Co.,Ltd. Registration number: Y2021990000958 |
|
PC01 | Cancellation of the registration of the contract for pledge of patent right |